Table 3

Mean time (weeks) to achieving response according to the American College of Rheumatology (ACR)

Degree of improvementPlacebo (n = 70)*Adalimumab
20 mg (n = 71)*40 mg (n = 70)*80 mg (n = 72)*
NA, not applicable.
*Group numbers indicate initial size of each group, with the exception of the adalimumab 20 mg group, which does not include the patient with Felty’s syndrome who was withdrawn after the first dose. Withdrawals and rescues were considered treatment failures.
⩾20% (ACR20)
⩾50% (ACR50)
⩾70% (ACR70)NA7.87.06.9